MedDataX Logo

Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

NCT ID: NCT00137410

Last Updated: 2008-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-11-30

Study Completion Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis,Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Celebrex

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;
* patients in flare

Exclusion Criteria

* any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA
* clinical or radiological evidence of chondrocalcinosis
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pfizer, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Rutigliano, BA, Italy

Site Status

Pfizer Investigational Site

Arenzano (GE), , Italy

Site Status

Pfizer Investigational Site

Cagliari - Monserrato, , Italy

Site Status

Pfizer Investigational Site

Foggia, , Italy

Site Status

Pfizer Investigational Site

Genova, , Italy

Site Status

Pfizer Investigational Site

Genova, , Italy

Site Status

Pfizer Investigational Site

Jesi ( AN), , Italy

Site Status

Pfizer Investigational Site

Milan, , Italy

Site Status

Pfizer Investigational Site

Milan, , Italy

Site Status

Pfizer Investigational Site

Padua, , Italy

Site Status

Pfizer Investigational Site

Palermo, , Italy

Site Status

Pfizer Investigational Site

Pavia, , Italy

Site Status

Pfizer Investigational Site

Potenza, , Italy

Site Status

Pfizer Investigational Site

Roma, , Italy

Site Status

Pfizer Investigational Site

Siena, , Italy

Site Status

Pfizer Investigational Site

Venezia, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=635-IFL-0508-015&StudyName=Celebrex+Short+Versus+Long+Therapy+In+Ostheoarthritis+Of+The+Knee

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3191091

Identifier Type: -

Identifier Source: secondary_id

635-IFL-0508-015

Identifier Type: -

Identifier Source: org_study_id